Navigation Links
Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
Date:7/30/2008

development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inh
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
2. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
5. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
6. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
8. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
9. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
10. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
11. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Kingston, Ontario (PRWEB) May 21, 2015 ... entered into an exclusive North American distribution agreement ... microbiology testing system. , With more than 160 ... of products and services for laboratory and production ... choice, operational excellence and differentiated services to enable ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... report commissioned by the U.S. Department of Energy has ... of producing hydrogen fuel from sunlight is the only ... meet future cost targets set by the federal agency. ... Alan Weimer,s research team of CU-Boulder,s chemical and biological ...
... Stem Cell Assurance, Inc. (SCLZ.PK) announced today ... Securities on Form 10 pursuant to Section 12(g) of the ... financial statements as of December 31, 2009 and 2010 and ... July 11, 2011, the Company will become an SEC reporting ...
... Dan Neumeister, FACHE, principal of Neumeister Healthcare Management Services ... selected by Chase Brexton Health Services (CBHS) of Baltimore, ... effective May 1, 2011. Neumeister is serving in this ... fills the position. As CBHS,s top ...
Cached Biology Technology:CU method projected to meet DOE cost targets for solar thermal hydrogen fuel production 2Regional Healthcare Management Firm Goes National 2
(Date:5/21/2015)... 2015 According to a ... (Hardware, Software, Services), by Applications (Surveillance (Airborne, Maritime, ... End-Users (Military & Defense & Commercial) - Global ... Market is expected to grow from $7252.0 Million ... a Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... to drugs, alcohol and tobacco in utero is bad ... have been hard to tease out in humans. Often ... factors like poverty can also influence brain development. ... brain scans, led by Childrens Hospital Boston neurologist Michael ...
... scientists are now flying through springtime Arctic pollution to ... summertime sea ice is melting - faster than predicted. ... university colleagues in Fairbanks, Alaska, to conduct the study ... our eyes, said A.R. Ravishankara, director of the chemistry ...
... Endometriosis is a poorly understood condition that incapacitates and affects ... world. In the US, it affects approximately six million women ... year. It is a chronic painful disease which occurs ... in the area of the ovaries and fallopian tubes, but ...
Cached Biology News:Your baby's brain on drugs (and alcohol and tobacco) 2NOAA aircraft to probe arctic pollution 2New study finds uncontrollable stress worsens symptoms of endometriosis 2New study finds uncontrollable stress worsens symptoms of endometriosis 3
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
...
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
Biology Products: